The new article provides further clarifications regarding the design of a clinical study, as well as the risk management approach to be followed.
Table of content
The Egyptian Drug Authority (EDA), the country’s regulatory agency in the sphere of healthcare products, has published a guidance document dedicated to preclinical testing and clinical investigation for medical devices. The document provides an overview of the applicable regulatory requirements, as well as additional clarifications and recommendations to be taken into consideration by medical device manufacturers and other parties involved in order to ensure compliance.
At the same time, it is important to mention that provisions of the guidance are non-binding in their legal nature, nor they are intended to introduce new rules or impose new obligations. Moreover, recommendations provided in the guidance could be subject to changes, should such changes be reasonably necessary to reflect corresponding amendments to the underlying legislation.
General Principles of Clinical Investigation Design
To ensure robust and ethical clinical investigations, the design should comply with the following principles:
- Risk Management: Minimize undue risks and comply with regulatory and ethical requirements.
- Scientific Rigor: Include clear objectives, statistical considerations, and relevance to residual risks and clinical performance.
- Influential Factors: Consider variables such as device type, patient demographics, exposure type, performance claims, and alternative treatments.
- Unique Challenges: Account for variability introduced by the healthcare professional or patient operating the device, as this significantly impacts clinical outcomes.
Justification for Study Design
As further explained by the EDA, the design justification should align with:
- Preclinical Data and Risk Assessment: Use results from evaluations and assessments to define study parameters.
- Endpoints and Controls: Identify relevant endpoints confounding factors and choose appropriate control groups (e.g., active, sham, or historical).
- Bias Minimization: Employ methods like randomization and blinding to ensure objectivity.
- Scientific Validity: The investigation must demonstrate clinical relevance and confirm the device’s benefit-risk profile.
Challenges specific to medical devices include accounting for user skills, variability in device performance, and operational challenges during study design.
Key Considerations for Clinical Investigation Protocols
The document also outlines the key aspects to be taken into consideration by the parties responsible for clinical investigations in order to ensure the accuracy and reliability of their results.
Essential Elements:
- Clear objectives and endpoints
- Risk minimization for subjects and researchers
- Detailed adverse event definitions and reporting
- Appropriate subject populations and study designs
- Statistical methodologies tailored to clinically relevant endpoints
Study Design Configurations:
- Parallel, crossover, or cohort studies
- Superiority, non-inferiority, or equivalence comparisons
- Duration and follow-up tailored to study objectives
Statistical Plan:
- Include sample size calculations, subgroup analyses, and management of missing data.
- Address potential learning curve issues and interim analyses.
- Ensure statistical evaluations reflect meaningful, clinically significant outcomes.
Uncertainty in study protocols should be resolved through discussions with regulatory authorities.
Risk Assessment During Clinical Investigations
In accordance with the applicable regulatory requirements, risks emerging during clinical investigations are managed through:
- Preliminary Risk Analysis: Triggered by events impacting subject or user safety. May result in documenting rationale for continuing or revising the risk assessment.
- Comprehensive Risk Assessment: Conducted if unacceptable risks are identified. May involve external input from Data Monitoring Committees (DMC) or expert advisors. Outcomes include:
- Continuation of the study with revisions to the benefit-risk analysis.
- Termination of the study if corrective actions compromise validity or are not feasible.
All risk assessments must be documented, and EDA must be notified in cases of significant changes or study termination.
Final Study Report
The results of the clinical investigation are compiled into a final study report, which:
- Forms part of the clinical data for the device’s evaluation.
- Integrates into the clinical evaluation report to support conformity assessments.
The final report is a critical component, summarizing outcomes, analyses, and risk management throughout the investigation.
Conclusion
In summary, clinical investigation study design for medical devices requires careful planning, robust justification, and rigorous risk management. Thus, manufacturers can ensure that clinical data generated are meaningful and valid for assessing safety, performance, and effectiveness by addressing unique challenges and adhering to ethical, scientific, and regulatory standards.
How Can RegDesk Help?
RegDesk is an AI-powered Regulatory Information Management System that provides medical device companies with regulatory intelligence for over 120 markets worldwide. It can help you prepare and publish global applications, manage standards, run change assessments, and obtain real-time alerts on regulatory changes through a centralized platform. Global expansion has never been this simple.
